Using a new device to monitor heart pressure in patients recovering from heart failure
Official title: A Prospective, Observational, Single Centre Study to Assess the Feasibility of the Data Harvested by the Acorai Intracardiac Pressure Monitoring (ICPM) System in Predicting Prognosis in Patients Discharged From Hospital After Treatment for Acute Decompensated Heart Failure
Run by Royal Brompton & Harefield NHS Foundation Trust · NCT06397833 · Data updated 2026-11-12
This study is testing a new device that measures heart pressure in patients recovering from heart failure to see if it can help doctors predict who might get worse and improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Uxbridge, Middlesex) |
| Status | Recruiting |
| Started | April 29, 2024 |
| Main results expected | February 1, 2026 |
| Study ends | February 1, 2027 |
| Registry record updated | April 8, 2025 |
| Trial ID | NCT06397833 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients who are medically fit for discharge after treatment for decompensated heart failure and require intravenous diuretic therapy.
✕Probably not a fit
Patients who are pregnant or those deemed unsuitable for the study by the investigator may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the Acorai Heart Monitor, a non-invasive device designed to measure intracardiac pressures in patients discharged from the hospital after treatment for acute decompensated heart failure. By placing the device on the patient's chest, it collects data on cardiac output and intracardiac pressures, which are crucial for predicting patient outcomes. The goal is to determine the feasibility of using this device to identify patients at risk of deterioration and to assess which data points best predict survival and major adverse cardiac events. This approach aims to provide a quick, easy-to-use monitoring tool that can be utilized by healthcare practitioners or patients themselves.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and management of heart failure patients, potentially reducing hospital readmissions and improving survival rates.
How similar studies have gone: While similar studies have explored non-invasive monitoring techniques, the specific use of the Acorai device in this context is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Subjects must meet all the following criteria to be eligible for participation in the clinical investigation 1. Subjects medically fit for discharge following an admission to Hospital with decompensated heart failure requiring intravenous diuretic therapy 2. Subject is willing and physically able to comply with the specified evaluations as per clinical investigation plan, as assessed by the investigator. 3. Subject is able to provide written consent to participate in the study Exclusion Criteria: 1. Pregnancy 2. Discretionary exclusion when, in the opinion of the investigator, the inclusion of a potential subject is not in their best interest or not in the interest of compliant performance of the clinical trial
Where it's running
-
Harefield Hospital
Uxbridge, Middlesex, United Kingdom Recruiting
Study contacts
- Study coordinator: Owais Dar, MB ChB MD Res
- Email: o.dar@rbht.nhs.uk
- Phone: 01895828933
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Bioimpedance-guided fluid management for decompensated heart failure
This test sees if using bedside bioimpedance measurements to guide diuretic treatment helps people hospitalized with worsening heart failure manage fluid and reduce extra treatment or rehospitalization within 90 days.
-
Using BIOMONITOR IV to track heart rhythm and warning signs in people with heart failure
This project will test whether a small implanted monitor called BIOMONITOR IV can track irregular heartbeats and body signals in people with heart failure who do not have ICD/CRT devices to see if it can warn doctors before the heart failure gets worse.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
Using colchicine to treat acutely decompensated heart failure with reduced ejection fraction
This study is testing if colchicine, an anti-inflammatory medication, can help people in the hospital with heart failure feel better and improve their heart function.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
-
Myocardial Energetics Across Cardiovascular Disease Spectrum Using 31P-MRS
Researchers are testing whether phosphorus-31 magnetic resonance spectroscopy (31P-MRS) can map heart energy metabolism across healthy people and patients with various heart conditions.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.